{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:07:52Z","timestamp":1795039672586,"version":"4.10.2"},"reference-count":223,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020266","name":"Ministerio de Ciencia, Tecnolog\u00eda, Conocimiento e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["NCN19_168"],"award-info":[{"award-number":["NCN19_168"]}],"id":[{"id":"10.13039\/100020266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1201039"],"award-info":[{"award-number":["1201039"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451-03-47\/2023-01\/200015"],"award-info":[{"award-number":["451-03-47\/2023-01\/200015"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","award":["ICN09_016\/ICN 2021_045"],"award-info":[{"award-number":["ICN09_016\/ICN 2021_045"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.heliyon.2024.e25081","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T02:32:11Z","timestamp":1705890731000},"page":"e25081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities"],"prefix":"10.1016","volume":"10","author":[{"given":"Milica","family":"Vukoti\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suncica","family":"Kapor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Cokic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9951-8990","authenticated-orcid":false,"given":"Juan F.","family":"Santibanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e25081_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.2","article-title":"Haematopoietic stem cells: past, present and future","volume":"3","author":"Ng","year":"2017","journal-title":"Cell Death Discov"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib2","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1097\/HS9.0000000000000737","article-title":"Embryonic origins of the hematopoietic system: hierarchies and heterogeneity","volume":"6","author":"Vink","year":"2022","journal-title":"Hemasphere"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib3","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.3390\/ijms24065862","article-title":"Hematopoietic stem cells and the immune system in development and aging","volume":"24","author":"Shevyrev","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2015.160","article-title":"Navigating the bone marrow niche: translational insights and cancer-driven dysfunction","volume":"12","author":"Reagan","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib5","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/HS9.0000000000000151","article-title":"Mesenchymal stromal cells: role in the BM niche and in the support of hematopoietic stem cell transplantation","volume":"2","author":"Crippa","year":"2018","journal-title":"Hemasphere"},{"key":"10.1016\/j.heliyon.2024.e25081_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.884024","article-title":"Bone marrow niches and tumour cells: lights and shadows of a mutual relationship","volume":"13","author":"Granata","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/14728222.2020.1744850","article-title":"The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies","volume":"24","author":"Behrmann","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3892\/ol.2021.12578","article-title":"New progress in the study of germline susceptibility genes of myeloid neoplasms","volume":"21","author":"Bi","year":"2021","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"7308","key":"10.1016\/j.heliyon.2024.e25081_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09262","article-title":"Mesenchymal and haematopoietic stem cells form a unique bone marrow niche","volume":"466","author":"M\u00e9ndez-Ferrer","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5045\/br.2016.51.4.225","article-title":"Mesenchymal stromal cells in myeloid malignancies","volume":"51","author":"Schroeder","year":"2016","journal-title":"Blood Res"},{"key":"10.1016\/j.heliyon.2024.e25081_bib12","series-title":"The Bone Marrow Stromal Niche: A New Master Regulator of Hematological Myeloid Malignancies","first-page":"p225","author":"Vgenopoulou","year":"2020"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e25081_bib13","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of hematological malignancies","volume":"18","author":"Rodriguez-Abreu","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib14","first-page":"e78","article-title":"Update on the classification of myeloid neoplasms: the 2016 revised World Health Organization classification of hematopoietic and lymphoid neoplasms","volume":"00","author":"Sangiorgio","year":"2019","journal-title":"Adv Cell Gene Ther"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e25081_bib15","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/bloodadvances.2018019224","article-title":"Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories","volume":"2","author":"Loghavi","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib16","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00018-017-2725-4","article-title":"Role of the microenvironment in myeloid malignancies","volume":"75","author":"Goulard","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"10393","key":"10.1016\/j.heliyon.2024.e25081_bib18","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib19","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"'Acute myeloid leukemia: a comprehensive review and 2016 update'","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s11864-022-01021-8","article-title":"Pathogenic mechanisms in acute myeloid leukemia","volume":"23","author":"Chakraborty","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib21","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e25081_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OTT.S236740","article-title":"FMS-like tyrosine kinase 3 inhibitors in the treatment of acute myeloid leukemia: an update on the emerging evidence and safety profile","volume":"16","author":"Garciaz","year":"2023","journal-title":"OncoTargets Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2024.e25081_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103164","article-title":"Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways","volume":"157","author":"Taghiloo","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5045\/br.2014.49.4.216","article-title":"Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease","volume":"49","author":"Visconte","year":"2014","journal-title":"Blood Res"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e25081_bib27","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib28","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25081_bib29","series-title":"Chronic Myeloid Neoplasias and Clonal Overlap Syndromes: Epidemiology, Pathophysiology and Treatment Options","first-page":"153","article-title":"Myelodysplastic syndromes (MDS)","author":"Pleyer","year":"2010"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/cells12040627","article-title":"Molecular drivers of myelodysplastic neoplasms (MDS)-Classification and prognostic relevance","volume":"12","author":"Hoff","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib31","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib32","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.24984","article-title":"Cause of death in patients with lower-risk myelodysplastic syndrome","volume":"116","author":"Dayyani","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005792-197605000-00005","article-title":"Causes of death in adults with acute leukemia","volume":"55","author":"Chang","year":"1976","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.heliyon.2024.e25081_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113905","article-title":"Myelodysplastic neoplasms: an overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment","volume":"156","author":"Marques","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib35","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e25081_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-016-0263-4","article-title":"Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications","volume":"9","author":"Pleyer","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-2141.2000.01868.x","article-title":"Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes","volume":"108","author":"Climent","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e25081_bib38","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e25081_bib39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","article-title":"The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes","volume":"133","author":"Sallman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25081_bib40","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ctrv.2007.07.021","article-title":"The pathogenesis of myelodysplastic syndromes (MDS)","volume":"33","author":"Platzbecker","year":"2007","journal-title":"Cancer Treat Rev."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.exphem.2015.05.016","article-title":"Deconstructing innate immune signaling in myelodysplastic syndromes","volume":"43","author":"Varney","year":"2015","journal-title":"Experimental hematology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MOH.0000000000000218","article-title":"New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms","volume":"23","author":"Passamonti","year":"2016","journal-title":"Curr. Opin. Hematol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25081_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","article-title":"The Philadelphia chromosome in leukemogenesis","volume":"35","author":"Kang","year":"2016","journal-title":"Chin. J. Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib45","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","article-title":"Chronic myeloid leukemia: beyond BCR-ABL1","volume":"13","author":"Zhou","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2024.e25081_bib46","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib47","doi-asserted-by":"crossref","DOI":"10.1053\/j.semdp.2023.04.007","article-title":"Advances in molecular evaluation of myeloproliferative neoplasms","author":"Li","year":"2023","journal-title":"Semin. Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/cells10010117","article-title":"Chronic myeloid leukemia: a model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e25081_bib49","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1158\/0008-5472.CAN-08-1101","article-title":"BCR\/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair","volume":"68","author":"Cramer","year":"2008","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib50","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib51","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib52","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e25081_bib53","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.7314\/APJCP.2015.16.17.7415","article-title":"Chronic myeloid leukemia--prognostic value of mutations","volume":"16","author":"Kaleem","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12185-022-03510-w","article-title":"Genetic landscape of chronic myeloid leukemia","volume":"117","author":"Ochi","year":"2023","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11899-022-00679-z","article-title":"Therapy resistance and disease progression in CML: mechanistic links and therapeutic strategies","volume":"17","author":"Ng","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cells12010105","article-title":"Impact of molecular biology in diagnosis, prognosis, and therapeutic management of BCR::ABL1-Negative myeloproliferative neoplasm","volume":"12","author":"Abbou","year":"2022","journal-title":"Cells"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e25081_bib58","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib59","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/ijms22041906","article-title":"Inflammatory microenvironment and specific T cells in myeloproliferative neoplasms: immunopathogenesis and novel immunotherapies","volume":"22","author":"Nasillo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e25081_bib60","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14740\/jh1042","article-title":"Acute myeloid leukemia following myeloproliferative neoplasms: a review of what we know, what we do not know, and emerging treatment strategies","volume":"11","author":"McKinnell","year":"2022","journal-title":"J Hematol"},{"key":"10.1016\/j.heliyon.2024.e25081_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2016.70.7968","article-title":"Genomics of myeloproliferative neoplasms","volume":"35","author":"Zoi","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib64","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e25081_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","article-title":"Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN","volume":"366","author":"Pasca","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.heliyon.2024.e25081_bib66","article-title":"Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation","volume":"2015","author":"Hermouet","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib67","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.3390\/ijms23094573","article-title":"Molecular pathogenesis of myeloproliferative neoplasms: from molecular landscape to therapeutic implications","volume":"23","author":"Morsia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib68","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Current hematologic malignancy reports"},{"key":"10.1016\/j.heliyon.2024.e25081_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.750346","article-title":"Immune dysregulation and infectious complications in MPN patients treated with JAK inhibitors","volume":"12","author":"Cattaneo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4062\/biomolther.2017.260","article-title":"Roles of mesenchymal stem cells in tissue regeneration and immunomodulation","volume":"27","author":"Ayala-Cuellar","year":"2019","journal-title":"Biomol Ther (Seoul)"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib72","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2016-11-696070","article-title":"The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications","volume":"129","author":"Medyouf","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib73","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.heliyon.2024.e25081_bib74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jor.1100090504","article-title":"Mesenchymal stem cells","volume":"9","author":"Caplan","year":"1991","journal-title":"J. Orthop. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11373-004-8183-7","article-title":"T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression","volume":"12","author":"Klyushnenkova","year":"2005","journal-title":"J. Biomed. Sci."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib76","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","article-title":"SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells","volume":"121","author":"Kiel","year":"2005","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib77","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/art.34434","article-title":"Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity","volume":"64","author":"Churchman","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib78","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/stem.1941","article-title":"Prospectively isolated human bone marrow cell-derived MSCs support primitive human CD34-negative hematopoietic stem cells","volume":"33","author":"Matsuoka","year":"2015","journal-title":"Stem Cell."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib79","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1084\/jem.20122252","article-title":"PDGFR\u03b1 and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion","volume":"210","author":"Pinho","year":"2013","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib80","doi-asserted-by":"crossref","first-page":"30015","DOI":"10.3390\/ijms161226215","article-title":"Mesenchymal stem cell-mediated effects of tumor support or suppression","volume":"16","author":"Rhee","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib81","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3390\/cancers12082107","article-title":"Role of MSC in the tumor microenvironment","volume":"12","author":"Hass","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib82","first-page":"321","article-title":"Tumor microenvironment: bone marrow-mesenchymal stem cells as key players","volume":"1836","author":"Barcellos-de-Souza","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib83","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/0963689719837897","article-title":"The pros and cons of mesenchymal stem cell-based therapies","volume":"28","author":"Musia\u0142-Wysocka","year":"2019","journal-title":"Cell Transplant."},{"key":"10.1016\/j.heliyon.2024.e25081_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.637725","article-title":"Immunomodulatory properties of mesenchymal stromal cells: an update","volume":"9","author":"M\u00fcller","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00005-018-0531-9","article-title":"Roles of myeloid-derived suppressor cells in cancer metastasis: immunosuppression and beyond","volume":"67","author":"Pastaki Khoshbin","year":"2019","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.heliyon.2024.e25081_bib86","article-title":"Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications","volume":"2015","author":"86-Castro-Manrreza","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.heliyon.2024.e25081_bib87","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fcell.2020.00447","article-title":"The multifaceted roles of MSCs in the tumor microenvironment: interactions with immune cells and exploitation for therapy","volume":"8","author":"Papait","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib88","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib89","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12013-011-9319-9","article-title":"Unresolved inflammation and cancer: loss of natural immune surveillance as the correct 'target' for therapy! Seeing the 'Elephant' in the light of logic","volume":"62","author":"Khatami","year":"2012","journal-title":"Cell Biochem. Biophys."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib90","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/mc.23206","article-title":"Myeloid derived suppressor cells in cancer, premalignancy and inflammation: a roadmap to cancer immunoprevention","volume":"59","author":"Sivagnanalingam","year":"2020","journal-title":"Mol. Carcinog."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e25081_bib91","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0301-472X(03)00110-3","article-title":"HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells","volume":"31","author":"Le Blanc","year":"2003","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib92","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5581\/1516-8484.20130017","article-title":"Immunological characteristics of mesenchymal stem cells","volume":"35","author":"Machado Cde","year":"2013","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jocit.2014.12.001","article-title":"Mesenchymal stem cells: immunomodulatory capability and clinical potential in immune diseases","volume":"2","author":"Zhao","year":"2016","journal-title":"Journal of Cellular Immunotherapy"},{"key":"10.1016\/j.heliyon.2024.e25081_bib94","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25081_bib95","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3389\/fonc.2019.01135","article-title":"The yin and yang of the bone marrow microenvironment: pros and cons of mesenchymal stromal cells in acute myeloid leukemia","volume":"9","author":"Ciciarello","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib96","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs","volume":"10","author":"Weiss","year":"2019","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib97","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/01.TP.0000082540.43730.80","article-title":"Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells","volume":"76","author":"Rasmusson","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib98","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-13-1656","article-title":"Mesenchymal stem cells use Ido to regulate immunity in tumor microenvironment","volume":"74","author":"Ling","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib99","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/cdd.2013.149","article-title":"Phylogenetic distinction of iNOS and Ido function in mesenchymal stem cell-mediated immunosuppression in mammalian species","volume":"21","author":"Su","year":"2014","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib100","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/eji.200738129","article-title":"IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease","volume":"38","author":"Polchert","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib101","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ebiom.2018.01.002","article-title":"Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-\u03b3","volume":"28","author":"Kim","year":"2018","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib102","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","article-title":"Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation","volume":"103","author":"Meisel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25081_bib103","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs","volume":"10","author":"Weiss","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib104","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jcyt.2014.07.004","article-title":"Tryptophan concentration is the main mediator of the capacity of adipose mesenchymal stromal cells to inhibit T-lymphocyte proliferation in vitro","volume":"16","author":"Menta","year":"2014","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213170","article-title":"Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress","volume":"14","author":"Laing","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib107","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-Dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014247","article-title":"IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis","volume":"5","author":"Bouffi","year":"2010","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib109","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1177\/0963689718780304","article-title":"Preconditioning enhances the therapeutic effects of mesenchymal stem cells on colitis through PGE2-mediated T-cell modulation","volume":"27","author":"Yang","year":"2018","journal-title":"Cell Transplant."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/10245332.2017.1333245","article-title":"Interferon-\u03b3 mediates the immunosuppression of bone marrow mesenchymal stem cells on T-lymphocytes in vitro","volume":"23","author":"Liang","year":"2018","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib111","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.TP.0000045055.63901.A9","article-title":"Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation","volume":"75","author":"Tse","year":"2003","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cellimm.2010.06.006","article-title":"Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources","volume":"264","author":"Najar","year":"2010","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib113","article-title":"PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.scr.2011.04.001","article-title":"Mesenchymal stromal cells upregulate CD39 and increase adenosine production to suppress activated T-lymphocytes","volume":"7","author":"Saldanha-Araujo","year":"2011","journal-title":"Stem Cell Res."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib115","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3727\/096368910X546553","article-title":"Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation","volume":"20","author":"Sattler","year":"2011","journal-title":"Cell Transplant."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib116","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.imlet.2015.06.005","article-title":"The MSC curtain that stops the immune system","volume":"168","author":"Caplan","year":"2015","journal-title":"Immunol. Lett."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib117","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1182\/blood-2004-04-1407","article-title":"Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo","volume":"105","author":"Erdmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e25081_bib118","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib119","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3389\/fchem.2019.00823","article-title":"The structural biology of galectin-ligand recognition: current advances in modeling tools, protein engineering, and inhibitor design","volume":"7","author":"Modenutti","year":"2019","journal-title":"Front. Chem."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3892\/ijo.2010.869","article-title":"Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins","volume":"38","author":"Sioud","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib121","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jcyt.2015.12.004","article-title":"Galectin-1 is a local but not systemic immunomodulatory factor in mesenchymal stromal cells","volume":"18","author":"Fajka-Boja","year":"2016","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib122","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4110\/in.2015.15.5.241","article-title":"Galectin-9 is involved in immunosuppression mediated by human bone marrow-derived clonal mesenchymal stem cells","volume":"15","author":"Kim","year":"2015","journal-title":"Immune Netw"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib123","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.327","article-title":"Mesenchymal stem cells and immunomodulation: current status and future prospects","volume":"7","author":"Gao","year":"2016","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib124","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/stem.2509","article-title":"Mesenchymal stromal cell secretion of programmed death-1 ligands regulates T cell mediated immunosuppression","volume":"35","author":"Davies","year":"2017","journal-title":"Stem Cell."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib125","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/eji.200425405","article-title":"Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway","volume":"35","author":"Augello","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib126","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/cr.2008.80","article-title":"A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1","volume":"18","author":"Sheng","year":"2008","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib127","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jcyt.2015.07.018","article-title":"Interferon-\u03b3 and tumor necrosis factor-\u03b1 promote the ability of human placenta-derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4(+)interleukin-10(+) and CD8(+)interleukin-10(+)Treg subsets","volume":"17","author":"Li","year":"2015","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tice.2012.09.002","article-title":"Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34\u207a cells: a comparison with human bone marrow-derived mesenchymal stem cells","volume":"45","author":"Luan","year":"2013","journal-title":"Tissue Cell"},{"key":"10.1016\/j.heliyon.2024.e25081_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2020.618308","article-title":"Mesenchymal stromal cells as a cellular target in myeloid malignancy: chances and challenges in the genome editing of stromal alterations","volume":"2","author":"Banjanin","year":"2021","journal-title":"Front Genome Ed"},{"key":"10.1016\/j.heliyon.2024.e25081_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.857045","article-title":"Regulation of malignant myeloid leukemia by mesenchymal stem cells","volume":"10","author":"Tan","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12185-008-0030-6","article-title":"Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60\/VCR","volume":"87","author":"Liang","year":"2008","journal-title":"Int. J. Hematol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib132","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1042\/CBI20110595","article-title":"Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) inhibit the proliferation of K562 (human erythromyeloblastoid leukaemic cell line)","volume":"36","author":"Fonseka","year":"2012","journal-title":"Cell Biol. Int."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib133","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2014.11.004","article-title":"c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia","volume":"39","author":"Xia","year":"2015","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib134","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e25081_bib135","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.18632\/oncotarget.7964","article-title":"Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia","volume":"7","author":"Takam Kamga","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e25081_bib136","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fimmu.2017.00106","article-title":"Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms","volume":"8","author":"Brenner","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib137","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/bjh.17940","article-title":"Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells","volume":"196","author":"Ahmed","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib138","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0301-472X(01)00612-9","article-title":"Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5)","volume":"29","author":"Garrido","year":"2001","journal-title":"Exp. Hematol."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e25081_bib139","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2013-06-511527","article-title":"Reciprocal leukemia-stroma VCAM-1\/VLA-4-dependent activation of NF-\u03baB mediates chemoresistance","volume":"123","author":"Jacamo","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242809","article-title":"Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-\u03b2-p38-ALDH2 pathway","volume":"15","author":"Yuan","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib141","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/2211-5463.13165","article-title":"METTL3 mediates bone marrow mesenchymal stem cell adipogenesis to promote chemoresistance in acute myeloid leukaemia","volume":"11","author":"Pan","year":"2021","journal-title":"FEBS Open Bio"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.17","article-title":"Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration","volume":"5","author":"Huang","year":"2015","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib143","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/leu.2008.361","article-title":"Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome","volume":"23","author":"Lopez-Villar","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib144","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/labinvest.2014.110","article-title":"CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes","volume":"94","author":"Abe-Suzuki","year":"2014","journal-title":"Lab. Invest."},{"issue":"20","key":"10.1016\/j.heliyon.2024.e25081_bib145","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1182\/blood-2011-03-343467","article-title":"Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts","volume":"118","author":"Blau","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib146","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/leu.2016.324","article-title":"Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients","volume":"31","author":"von der Heide","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib147","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/leu.2015.325","article-title":"Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia","volume":"30","author":"Geyh","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib148","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-14-3379","article-title":"Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia","volume":"75","author":"Kim","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib149","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.stemcr.2017.04.019","article-title":"Detailed characterization of mesenchymal stem\/stromal cells from a large cohort of AML patients demonstrates a definitive link to treatment outcomes","volume":"8","author":"Diaz de la Guardia","year":"2017","journal-title":"Stem Cell Rep."},{"issue":"14","key":"10.1016\/j.heliyon.2024.e25081_bib150","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","article-title":"Release of IFN\u03b3 by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells","volume":"28","author":"Corradi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib151","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1309\/AJCP71OPHKOTLSUG","article-title":"Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival","volume":"142","author":"Johnson","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib152","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s13287-018-1013-z","article-title":"Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival","volume":"9","author":"Corradi","year":"2018","journal-title":"Stem Cell Res. Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib153","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/10428190802455875","article-title":"Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases","volume":"49","author":"Zhi-Gang","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib154","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2014.08.008","article-title":"Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells","volume":"38","author":"Gul-Uluda\u011f","year":"2014","journal-title":"Leuk. Res."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e25081_bib155","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/sj.onc.1208405","article-title":"Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro","volume":"24","author":"Soenen-Cornu","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib156","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.canlet.2011.08.030","article-title":"Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes","volume":"317","author":"Zhao","year":"2012","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e25081_bib157","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1089\/scd.2011.0390","article-title":"Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes","volume":"21","author":"Aanei","year":"2012","journal-title":"Stem Cells Dev"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib158","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/leu.2013.193","article-title":"Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells","volume":"27","author":"Geyh","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib159","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/labinvest.2014.110","article-title":"CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes","volume":"94","author":"Abe-Suzuki","year":"2014","journal-title":"Lab. Invest."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib160","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/scd.2009.0286","article-title":"Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes","volume":"19","author":"Klaus","year":"2010","journal-title":"Stem Cells Dev"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e25081_bib161","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1089\/scd.2013.0283","article-title":"Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway","volume":"23","author":"Pavlaki","year":"2014","journal-title":"Stem Cells Dev"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib162","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/ejh.12385","article-title":"Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53\/p21 pathway in myelodysplastic syndromes","volume":"93","author":"Fei","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib163","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.scr.2012.04.001","article-title":"DLK1(PREF1) is a negative regulator of adipogenesis in CD105\u207a\/CD90\u207a\/CD34\u207a\/CD31\u207b\/FABP4\u207b adipose-derived stromal cells from subcutaneous abdominal fat pats of adult women","volume":"9","author":"Mitterberger","year":"2012","journal-title":"Stem Cell Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib164","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/s41598-021-85122-8","article-title":"Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression","volume":"11","author":"Weickert","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib165","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2014.02.014","article-title":"Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit","volume":"14","author":"Medyouf","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.heliyon.2024.e25081_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1078421","article-title":"The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib167","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.leukres.2006.12.016","article-title":"Impairment in immuno-modulatory function of Flk 1(+)CD31(-)CD34(-) MSCs from MDS-RA patients","volume":"31","author":"Han","year":"2007","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib168","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.15548","article-title":"Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity","volume":"183","author":"Wu","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib169","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2015-07-655860","article-title":"Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy","volume":"128","author":"Moschoi","year":"2016","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e25081_bib170","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood-2017-03-772939","article-title":"NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts","volume":"130","author":"Marlein","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib171","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12185-016-2028-9","article-title":"High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia","volume":"104","author":"Zhang","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"32","key":"10.1016\/j.heliyon.2024.e25081_bib172","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1074\/jbc.RA119.008037","article-title":"Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7\/JAK1\/STAT5 pathway","volume":"294","author":"Zhang","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib173","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib174","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.leu.2404489","article-title":"Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth","volume":"21","author":"Ramasamy","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib176","first-page":"29","article-title":"Influence of human bone marrow mesenchymal stem cells on proliferation of chronic myeloid leukemia cells","volume":"28","author":"Zhang","year":"2009","journal-title":"Ai Zheng"},{"issue":"Suppl 2","key":"10.1016\/j.heliyon.2024.e25081_bib177","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib178","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3892\/or.2013.2518","article-title":"Effect of bone marrow mesenchymal stem cells from blastic phase chronic myelogenous leukemia on the growth and apoptosis of leukemia cells","volume":"30","author":"Han","year":"2013","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e25081_bib179","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb3530","article-title":"Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis","volume":"19","author":"Decker","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182470","article-title":"Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis","volume":"12","author":"Ramos","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e25081_bib181","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-014-0092-2","article-title":"Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms","volume":"7","author":"Schneider","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e25081_bib182","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1158\/0008-5472.CAN-14-3696","article-title":"Osteogenic potential of mesenchymal stromal cells contributes to primary myelofibrosis","volume":"75","author":"Martinaud","year":"2015","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib183","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: insights and therapeutic opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.heliyon.2024.e25081_bib184","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/347270","article-title":"The hematopoietic niche in myeloproliferative neoplasms","volume":"2015","author":"Schmitt-Graeff","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib185","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib186","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.stem.2020.11.004","article-title":"Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis","volume":"28","author":"Leimk\u00fchler","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib187","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s12276-022-00742-y","article-title":"Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms","volume":"54","author":"Vukoti\u0107","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"7512","key":"10.1016\/j.heliyon.2024.e25081_bib188","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib189","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1158\/0008-5472.CAN-10-4002","article-title":"Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor","volume":"71","author":"Manshouri","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib190","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1097\/HS9.0000000000000168","article-title":"Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets","volume":"3","author":"Bizymi","year":"2019","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e25081_bib191","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nm.3364","article-title":"Differential regulation of myeloid leukemias by the bone marrow microenvironment","volume":"19","author":"Krause","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib192","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12185-017-2266-5","article-title":"Impact of inflammation on early hematopoiesis and the microenvironment","volume":"106","author":"Takizawa","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib193","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers10040104","article-title":"The critical role of inflammation in the pathogenesis and progression of myeloid malignancies","volume":"10","author":"Craver","year":"2018","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib194","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s40425-018-0432-9","article-title":"CD33\/CD3-bispecific T-cell engaging (BiTE\u00ae) antibody construct targets monocytic AML myeloid-derived suppressor cells","volume":"6","author":"Jitschin","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib195","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1038\/bcj.2015.73","article-title":"Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts","volume":"5","author":"Aliperta","year":"2015","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib196","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/jpet.106.109314","article-title":"Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling","volume":"319","author":"Leung","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e25081_bib197","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2017.186734","article-title":"Transforming growth factor \u03b21-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia","volume":"103","author":"Geyh","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib198","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib199","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14728222.2020.1744568","article-title":"TGF-beta: a master immune regulator","volume":"24","author":"Larson","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131761","article-title":"The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations","volume":"10","author":"Tian","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e25081_bib201","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MOH.0000000000000749","article-title":"Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia","volume":"30","author":"Brunner","year":"2023","journal-title":"Curr. Opin. Hematol."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e25081_bib202","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911526","article-title":"Therapeutic advances in immunotherapies for hematological malignancies","volume":"23","author":"Nogami","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib203","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood-2006-11-060087","article-title":"Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy","volume":"110","author":"Tsushima","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib204","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3390\/cancers12071763","article-title":"Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms","volume":"12","author":"Holmstr\u00f6m","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e25081_bib205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib206","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"429","key":"10.1016\/j.heliyon.2024.e25081_bib207","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e25081_bib208","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e25081_bib209","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1247135","article-title":"The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells","volume":"5","author":"Lu","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e25081_bib210","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6616391","article-title":"T cell exhaustion and CAR-T immunotherapy in hematological malignancies","volume":"2021","author":"Tang","year":"2021","journal-title":"BioMed Res. Int."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib211","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.heliyon.2024.e25081_bib212","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.618387","article-title":"Befriending the hostile tumor microenvironment in CAR T-cell therapy","volume":"11","author":"Lindo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e25081_bib213","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e25081_bib214","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/ijms24076300","article-title":"CAR T cell therapy: a versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e25081_bib215","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e25081_bib216","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e25081_bib217","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2019.05.002","article-title":"CD123 CAR T cells for the treatment of myelodysplastic syndrome","volume":"74","author":"Stevens","year":"2019","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib218","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e25081_bib219","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective killing of candidate AML stem cells by antibody targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood"},{"issue":"37","key":"10.1016\/j.heliyon.2024.e25081_bib220","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e25081_bib221","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML hematopoietic stem cells expressing IL1RAP can Be targeted by chimeric antigen receptor-engineered T cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib222","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/biomedicines10040804","article-title":"CAR-T cells\/-NK cells in cancer immunotherapy and the potential of MSC to enhance its efficacy: a review","volume":"10","author":"Chan","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e25081_bib223","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/cells9040873","article-title":"IL7-IL12 engineered mesenchymal stem cells (MSCs) improve A CAR T cell attack against colorectal cancer cells","volume":"9","author":"Hombach","year":"2020","journal-title":"Cells"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024011125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024011125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:29:26Z","timestamp":1775456966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024011125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":223,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2405844024011125"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25081","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e25081"}}